Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Pharmacokinetics"
DOI: 10.1007/s40262-018-0644-7
Abstract: Since its clinical introduction in 1998, the topoisomerase I inhibitor irinotecan has been widely used in the treatment of solid tumors, including colorectal, pancreatic, and lung cancer. Irinotecan therapy is characterized by several dose-limiting toxicities… read more here.
Keywords: individualization irinotecan; treatment; review; pharmacodynamics pharmacogenetics ... See more keywords
Molecular‐targeted therapy in advanced renal cell carcinoma based on pharmacokinetics, pharmacodynamics and pharmacogenetics: A proposed strategy
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Urology"
DOI: 10.1111/iju.13805
Abstract: In advanced renal cell carcinoma, a transition of drug therapies from cytokines to molecular‐targeted drugs and immune‐oncology drugs provides more clinical benefits to patients, while adequate management is required for various and sometimes serious adverse… read more here.
Keywords: renal cell; cell carcinoma; molecular targeted; pharmacodynamics pharmacogenetics ... See more keywords